Postmarketing Surveillance Study to Assess Handling and Patient Satisfaction on Berodual® Respimat® Solution for Inhalation in Comparison to a Powder Inhaler in Patients With Chronic Obstructive Pulmonary Disease
Completed
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- Drug: Berodual® Respimat® - inhaler
- First Posted Date
- 2014-09-04
- Last Posted Date
- 2014-09-04
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 150
- Registration Number
- NCT02231346
Post-marketing Surveillance of Berodual® Metered-dose Inhaler in the Treatment of Chronic Obstructive Respiratory Tract Disease
Completed
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- Drug: Berodual®
- First Posted Date
- 2014-09-04
- Last Posted Date
- 2014-09-04
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 3488
- Registration Number
- NCT02231437
Bioequivalence of a Fixed Dose Combination Tablet of Empagliflozin/Metformin Extended Release Compared With Mono Compound Tablets in Healthy Subjects
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2014-09-03
- Last Posted Date
- 2017-03-09
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 30
- Registration Number
- NCT02230995
- Locations
- 🇩🇪
Boehringer Ingelheim Investigational Site, Biberach an der Riss, Germany
Expanded Access Program of Nintedanib in Patients With Idiopathic Pulmonary Fibrosis
- Conditions
- Idiopathic Pulmonary Fibrosis
- First Posted Date
- 2014-09-03
- Last Posted Date
- 2019-02-08
- Lead Sponsor
- Boehringer Ingelheim
- Registration Number
- NCT02230982
- Locations
- 🇧🇷
UNIFESP Departamento de Medicina de Pneumologia, Sao Paulo - SP, Brazil
🇧🇷Irmandade da Santa Casa de Misericórdia de Porto Alegre, Porto Alegre, Brazil
🇧🇷Hospital das Clínicas de Sao Paulo - INCOR, Sao Paulo, Brazil
An International Observational Study of the Safety and Efficacy of Thrombolysis in Stroke
- First Posted Date
- 2014-09-03
- Last Posted Date
- 2014-09-03
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 593
- Registration Number
- NCT02229890
Study to Assess Clinical Response of Duloxetine in Patients Hospitalized for Severe Depression
- First Posted Date
- 2014-09-01
- Last Posted Date
- 2023-10-23
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 339
- Registration Number
- NCT02229825
Pharmacodynamics, Preliminary Pharmacokinetics and Tolerability of BIBB 1464 (Tablet) in Hyperlipemic Healthy Male Subjects
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- Drug: BIBB 1464 MS medium doseDrug: BIBB 1464 MS low doseDrug: BIBB 1464 MS high doseDrug: Placebo
- First Posted Date
- 2014-09-01
- Last Posted Date
- 2014-09-01
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 100
- Registration Number
- NCT02229773
Protocol for Post Marketing Surveillance of Actilyse Vial
- First Posted Date
- 2014-09-01
- Last Posted Date
- 2014-09-01
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 265
- Registration Number
- NCT02229799
Effect of Steady State TPV/r on Intracellular Concentrations of Zidovudine and Carbovir for Patients With HIV
Phase 1
Terminated
- Conditions
- HIV Infections
- Interventions
- First Posted Date
- 2014-09-01
- Last Posted Date
- 2014-09-01
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 3
- Registration Number
- NCT02229760
Efficacy and Safety of Meloxicam Suspension Versus Diclofenac Suspension or Nimesulide Suspension in Patients With a Diagnosis of Acute, Non-bacterial Pharyngitis, Pharyngotonsillitis or Laryngitis
- First Posted Date
- 2014-09-01
- Last Posted Date
- 2014-09-01
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 128
- Registration Number
- NCT02229747
© Copyright 2025. All Rights Reserved by MedPath